CoChat

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study

Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., Lane, R. · 2008 · Current Medical Research and Opinion

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The aim was to evaluate the efficacy, safety and tolerability of rivastigmine capsules in patients diagnosed with probable vascular dementia (VaD). METHODS: VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. VaD patients aged 50-85 years were randomized to rivastigmine capsules (3-12 mg/day) or placebo. Efficacy assessments included global and cognitive performances, activities of daily living and neuropsychiatric symptoms. Adverse events were recorded. Additional exploratory analyses determined whether heterogeneity in pathologies and symptoms extended to differential treatment effects. TRIAL REGISTRATION: NCT00099216. RESULTS: 710 patients were randomized. Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p< or = 0.05, intent-to-treat population [ITT]), but not other outcomes. Predominant adverse events were nausea and vomiting. Exploratory analyses indicated that older patients (> or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients. Younger patients, assumed less likely to have concomitant AD pathology, showed no efficacy response and were associated with slight elevations of blood pressure, cerebrovascular accidents and mortality. Rivastigmine-placebo differences in patients with, versus those without, medial temporal atrophy (also suggestive of concomitant AD) showed a numerical difference similar to that seen between the older versus younger patients, but did not attain statistical significance. CONCLUSION: Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. The efficacy apparent on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. This is supportive of an existing argument that the putative cholinergic deficit in VaD reflects the presence of concomitant Alzheimer pathology.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990802328142

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 8

  1. Heyman A, 1998, Consortium to Establish a Registry for Alzheimer's disease. Neurology, 51, 159
  2. Roman GC, 1993, Report of the NINDS-AIREN International Workshop. Neurology, 43, 250
  3. Gottfries CG, 1994, Dementia, 5, 163
  4. Erkinjuntti T, 2000, J Neural Transm Suppl, 59, 23
  5. Folstein MF, 1975, A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189
  6. Ferris SH, 1999, Alzheimer Dis Assoc Disord, 13, S140
  7. Corey-Bloom J, 1998, Int J Geriatr Psychopharmacol, 1, 55
  8. 10.1016/s1474-4422(07)70195-3 · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R.
Affiliations
  • King's College London (GB)
  • Westmoreland Neurology, Greensburg, Pennsylvania, USA
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Novartis (United States) (US)
  • Department of Neurology, Radiology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
  • Novartis (Switzerland) (CH)
Corresponding author
Ballard, C.
Venue
Current Medical Research and Opinion
Published
2008-07-30
Volume
24
Issue
9
Pages
2561-2574
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2150693120
Cited by
147
References
57
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 41 · 2019: 6 · 2018: 4 · 2017: 12 · 2016: 11 · 2015: 9 · 2014: 5 · 2013: 9 · 2012: 5
FWCI
4.44
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
rivastigmine, vascular dementia, cholinesterase inhibitors, cognitive performance, Alzheimer's disease pathology, medial temporal lobe atrophy, age differences in treatment response, adverse events, neuropsychiatric symptoms, activities of daily living
MeSH terms
Rivastigmine, Administration, Oral, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Prospective Studies, Dementia, Vascular, Treatment Outcome, Neuroprotective Agents, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. https://app.cochat.ai/papers/10.1185/03007990802328142
The paper
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008). Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802328142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.